Clinical and genetic correlates of soluble P-selectin in the community

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 20-31

  Lee, D S ^a,b   Larson, M G ^b   Lunetta, K L ^b   Dupuis, J ^b   Rong, J ^b   Keaney, J F ^c   Lipinska, I ^c   Baldwin, C T ^c   Vasan, R S ^b,c   Benjamin, Emelia J ^b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Genetics; Inflammation; P selectin; Polymorphism single nucleotide; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PROLINE; THREONINE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DIET RESTRICTION; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC LINKAGE; GLUCOSE BLOOD LEVEL; HERITABILITY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PEDIGREE ANALYSIS; PHENOTYPE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INHERITANCE PATTERNS; LINKAGE (GENETICS); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; P-SELECTIN; PEDIGREE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RESIDENCE CHARACTERISTICS; RISK FACTORS;

EID: 37548998609     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02805.x     Document Type: Article

References (70)

1. Minamino T., Kitakaze M, Sanada S, Asanuama H, Kurotobi T, Koretsune Y, Fukunami M, Kuzuya T, Hoki N, Hori M. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: Role of nitric oxide. Circulation 1998; 98: 1721-7.
2. Hillis GS, Terregino C, Taggart P, Killian A, Zhao N, Dalsey WC, Mangione A. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J 2002; 143: 235-41.
3. Ridker PM, Buring J.E, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
4. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
5. Kameda H, Morita I, Handa M, Kaburaki J, Yoshida T, Mimori T, Murota S, Ikeda Y. Re-expression of functional P-selectin molecules on the endothelial cell surface by repeated stimulation with thrombin. Br J Haematol 1997; 97: 348-55.
6. Khew-Goodall Y, Butcher CM, Litwin MS, Newlands S, Korpelainen EI, Noack LM, Berndt MC, Lopez AF, Gamble JR, Vadas MA. Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3. Blood 1996; 87: 1432-8.
7. Armstead VE, Minchenko AG, Schuhl RA, Hayward R, Nossuli TO, Lefer AM. Regulation of P-selectin expression in human endothelial cells by nitric oxide. Am J Physiol 1997; 273: H740-6.
8. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000; 101: 2290-5.
9. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, Beaudet AL. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997; 17: 1517-20.
10. Manka D, Collins RG, Ley K, Beaudet AL, Sarembock IJ. Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation 2001; 103: 1000-5.
11. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: Correlation with leukocyte recruitment to adherent platelets 1hour after injury. Circulation 2001; 103: 2501-7.
12. Koyama H, Maeno T, Fukumoto S, Shoji T, Yamane T, Yokoyama H, Emoto M, Shoji T, Tahara H, Inaba M, Hino M, Shioi A, Miki T, Nishizawa Y. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 2003; 108: 524-9.
13. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol 1994; 144: 952-61.
14. Jefferson AL, Massaro JM, Wolf PA, Seshadri S, Au R, Vasan RS, Larson MG, Meigs JB, Keaney JF Jr, Lipinska I, Kathiresan S, Benjamin EJ, DeCarli C. Inflammatory biomarkers are associated with total brain volume: The Framingham Heart Study. Neurology 2007; 68: 1032-8.
15. Thakore AH, Guo CY, Larson MG, Corey D, Wang TJ, Vasan RS, D'Agostino RB Sr, Lipinska I, Keaney JF Jr, Benjamin EJ, O'Donnell CJ. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol 2007; 99: 1598-602.
16. Keating FK, Whitaker DA, Kabbani SS, Ricci MA, Sobel BE, Schneider DJ. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol 2004; 94: 725-8.
17. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003; 101: 2661-6.
18. Marschang P, Friedrich GJ, Ditlbacher H, Stoeger A, Nedden DZ, Kirchmair R, Dienstl A, Pachinger O, Patsch JR. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Int J Cardiol 2006; 106: 183-90.
19. Fang L, Wei H, Mak KH, Xiong Z, Song J, Wang D, Lim YL, Chatterjee S. Markers of low-grade inflammation and soluble cell adhesion molecules in Chinese patients with coronary artery disease. Can J Cardiol 2004; 20: 1433-8.
20. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY. Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann Med 2005; 37: 61-6.
21. Hashimoto H, Kitagawa K, Kuwabara K, Hougaku H, Ohtsuki T, Matsumoto M, Hori M. Circulating adhesion molecules are correlated with ultrasonic assessment of carotid plaques. Clin Sci (Lond.) 2003; 104: 521-7.
22. Tregouet DA, Barbaux S, Escolano S, Tahri N, Golmard JL, Tiret L, Cambien F Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet 2002. 11: 2015-23.
23. Chironi G, Dosquet C, Del Pino M, Denarie N, Megnien JL, Drouet L, Bal dit SC, Levenson J, Simon A. Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men. Am J Hypertens 2006; 19: 1025-31.
24. Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Boerwinkle E. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2007; 195: E76-e82.
25. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. Science 2007; 316: 1488-91.
26. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443-53.
27. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979; 110: 281-90.
28. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: The Framingham Study. Ann NY Acad Sci 1963; 107: 539-56.
29. Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O'Connor GT, Rapoport DM, Redline S, Robbins J, Samet JM, Wahl PW. The Sleep Heart Health Study: Design, rationale, and methods. Sleep 1997; 20: 1077-85.
30. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997; 35: 2-3.
31. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-20.
32. Allison DB, Neale MC, Zannolli R, Schork NJ, Amos CI, Blangero J. Testing the robustness of the likelihood-ratio test in a variance-component quantitative-trait loci-mapping procedure. Am J Hum Genet 1999; 65: 531-44.
33. Dupuis J, Larson MG, Vasan RS, Massaro JM, Wilson PW, Lipinska I, Corey D, Vita JA, Keaney JF Jr, Benjamin EJ. Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q. Atherosclerosis 2005; 182: 307-14.
34. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62: 1198-211.
35. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: A unified multipoint approach. Am J Hum Genet 1996; 58: 1347-63.
36. Heath SC. Markov chain Monte Carlo segregation and linkage analysis for oligogenic models. Am J Hum Genet 1997; 61: 748-60.
37. Tang H.K, Siegmund D. Mapping quantitative trait loci in oligogenic models. Biostatistics 2001; 2: 147-62.
38. Emigh TH. A comparison of tests for Hardy-Weinberg equilibrium. Biometrics 1980; 36: 627-42.
39. Warnes G, Leisch F Population Genetics: R Package Version 1.1.3. 2005.
40. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
41. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-34.
42. Ihaka R, Gentleman R. R: A language for data analysis. J Comp Graph Stat 1996; 5: 299-314.
43. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001; 10: 591-7.
44. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: Server and survey. Nucleic Acids Res 2002; 30: 3894-900.
45. Barbaux SC, Blankenberg S, Rupprecht HJ, Francomme C, Bickel C, Hafner G, Nicaud V, Meyer J, Cambien F, Tiret L. Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 1668-73.
46. Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004; 44: 415-22.
47. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallen NH. Enhanced P-selectin expression and increased soluble CD40 ligand in patients with Type 1 diabetes mellitus and microangiopathy: Evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004; 47: 537-40.
48. Ponthieux A, Herbeth B, Droesch S, Haddy N, Lambert D, Visvikis S. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: The Stanislas study. Atherosclerosis 2004; 172: 299-308.
49. Davi G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, Bittolo BG. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-7.
50. Hixson JE, Blangero J. Genomic searches for genes that influence atherosclerosis and its risk factors. Ann NY Acad Sci 2000; 902: 1-7.
51. Diego VP, Almasy L, Dyer TD, Soler JM, Blangero J. Strategy and model building in the fourth dimension: A null model for genotype × age interaction as a Gaussian stationary stochastic process. BMC Genet 2003; 4 (Suppl. 1): S34.
52. Carter AM, Anagnostopoulou K, Mansfield MW, Grant PJ. Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease. J Thromb Haemost 2003; 1: 1718-23.
53. Miller MA, Kerry SM, Dong Y, Strazzullo P, Cappuccio FP. Association between the Thr715Pro P-selectin gene polymorphism and soluble P-selectin levels in a multiethnic population in South London. Thromb Haemost 2004; 92: 1060-5.
54. Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Wu KK, Boerwinkle E. P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: The Atherosclerosis Risk In Communities Study. Atherosclerosis 2006; 186: 74-9.
55. Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: A sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med 2007; 261: 384-91.
56. McCarthy JJ, Parker A, Salem R, Moliterno DJ, Wang Q, Plow EF, Rao S, Shen G, Rogers WJ, Newby LK, Cannata R, Glatt K, Topol EJ. Large scale association analysis for identification of genes underlying premature coronary heart disease: Cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004; 41: 334-41.
57. Anzej S, Bozic M, Antovic A, Peternel P, Gaspersic N, Rot U, Tratar G, Stegnar M Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. Thromb Res 2007; 120: 39-46.
58. Cleanthis M, Bhattacharya V, Smout J, Ashour H, Stansby G Platelet monocyte aggregates and monocyte chemoattractant protein-1 are not inhibited by aspirin in critical limb ischaemia. Eur J Vasc Endovasc Surg 2007; 33: 725-30.
59. Herrmann SM, Ricard S, Nicaud V, Mallet C, Evans A, Ruidavets JB, Arveiler D, Luc G, Cambien F. The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet 1998; 7: 1277-84.
60. Kee F, Morrison C, Evans AE, McCrum E, McMaster D, Dallongeville J, Nicaud V, Poirier O, Cambien F. Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study. Etude cas-temoin de l'infarctus myocarde. Heart 2000; 84: 548-52.
61. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: Is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007; 49: 1035-42.
62. Schafer A, Fraccarollo D, Vogt C, Flierl U, Hemberger M, Tas P, Ertl G, Bauersachs J. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol 2007; 73: 1367-75.
63. Utsumi K, Kawabe M, Hirama A, Ueda K, Kamada Y, Arii K, Komaba Y, Katsura K, Iino Y, Katayama Y. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta 2007; 377: 198-200.
64. Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T. LDL-apheresis reduces P-selectin, CRP and fibrinogen -possible important implications for improving atherosclerosis. Ther Apher Dial 2006; 10: 219-23.
65. Schaefer U, Kurz T, Bonnemeier H, Dendorfer A, Hartmann F, Schunkert H, Richardt G. Intracoronary enalaprilat during angioplasty for acute myocardial infarction: Alleviation of postischaemic neurohumoral and inflammatory stress? J Intern Med 2007; 261: 188-200.
66. Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, Wilhite DB, Comerota AJ. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006; 96: 738-43.
67. Nadar S, Blann AD, Lip GY. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients. Am J Hypertens 2006; 19: 970-7.
68. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-45.
69. Zoppini G, Targher G, Zamboni C, Venturi C, Cacciatori V, Moghetti P, Muggeo M. Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2006; 16: 543-9.
70. Fukushima S, Coppen SR, Varela-Carver A, Yamahara K, Sarathchandra P, Smolenski RT, Yacoub MH, Suzuki K. A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intracoronary route. Circulation 2006; 114: I251-6.